Skip to main content
Erschienen in: Journal of Cancer Survivorship 2/2009

01.06.2009

Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer

verfasst von: Linda C. Harlan, Carrie N. Klabunde, Anita H. Ambs, Todd Gibson, Leslie Bernstein, Anne McTiernan, Kathleen Meeske, Kathy B. Baumgartner, Rachel Ballard-Barbash

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe comorbidities in breast cancer patients at diagnosis and examine factors associated with self-reported comorbidities 30 months post-diagnosis.

Methods

Nine hundred forty one of 1,171 women had a medical record abstract and a follow-up survey in the Health, Eating, Activity and Lifestyle Study.

Results

We compared our breast cancer cohort to a contemporaneous nationally-representative sample of age, race/ethnicity and education matched women without cancer (n = 865). Breast cancer patients did not have substantially more comorbidities than women without breast cancer. Women with a hospital record of congestive heart failure significantly less often received chemotherapy or radiation following breast conserving surgery. In multivariate analysis, women who received chemotherapy alone (OR = 3.2; 95% CI: 1.5–6.8), chemotherapy plus radiation (OR = 1.9; 95% CI: 1.02–3.7) or radiation plus tamoxifen (OR = 1.9; 95% CI: 1.1–3.2) were significantly more likely to report at least one new comorbid condition following breast cancer diagnosis than women who received no chemotherapy, tamoxifen or radiation. Overall, women who received adjuvant therapy were more likely to have new comorbidities.

Conclusions

Comorbidities were not substantially different in breast cancer patients than the non-cancer matched controls. Future research should focus on efforts to minimize comorbidities related to chemotherapy and other combination therapy.
Literatur
1.
Zurück zum Zitat American Cancer Society.Cancer Facts and Figures. Atlanta: American Cancer Society; 2007. American Cancer Society.Cancer Facts and Figures. Atlanta: American Cancer Society; 2007.
3.
Zurück zum Zitat Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients age 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.1001/jama.285.7.885.CrossRef Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients age 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.​1001/​jama.​285.​7.​885.CrossRef
4.
Zurück zum Zitat Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716–26. doi:10.1093/jnci/88.11.716.PubMedCrossRef Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst. 1996;88:716–26. doi:10.​1093/​jnci/​88.​11.​716.PubMedCrossRef
6.
7.
Zurück zum Zitat Balasubramanian BA, Gandhi SK, Demissie K, et al. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older. Cancer Control. 2007;14:63–68.PubMed Balasubramanian BA, Gandhi SK, Demissie K, et al. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older. Cancer Control. 2007;14:63–68.PubMed
12.
Zurück zum Zitat Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMed Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMed
13.
Zurück zum Zitat Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.1001/jama.285.7.885.CrossRef Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.​1001/​jama.​285.​7.​885.CrossRef
19.
Zurück zum Zitat Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatmen. 2005;92:151–6. doi:10.1007/s10549-005-1410-8.CrossRef Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatmen. 2005;92:151–6. doi:10.​1007/​s10549-005-1410-8.CrossRef
20.
Zurück zum Zitat Geiger AM, Gischberg GM, Chen W, Bernsein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96:1528–36.PubMedCrossRef Geiger AM, Gischberg GM, Chen W, Bernsein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96:1528–36.PubMedCrossRef
Metadaten
Titel
Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer
verfasst von
Linda C. Harlan
Carrie N. Klabunde
Anita H. Ambs
Todd Gibson
Leslie Bernstein
Anne McTiernan
Kathleen Meeske
Kathy B. Baumgartner
Rachel Ballard-Barbash
Publikationsdatum
01.06.2009
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 2/2009
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-009-0084-3

Weitere Artikel der Ausgabe 2/2009

Journal of Cancer Survivorship 2/2009 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.